Andrx Plans Diltiazem ANDA Amendment In May; Biovail Delists Tiazac Patent
Executive Summary
Andrx plans to amend its ANDA for a generic version of Biovail's Tiazac in May following a request by FDA for additional data, the company said
You may also be interested in...
FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic
The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx
FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic
The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx
Biovail Says Tiazac Andrx Settlement “Satisfies” FTC; Patent Remains Listed
Biovail's Tiazac patent litigation settlement with Andrx satisfies the Federal Trade Commission's concerns regarding late-listed Tiazac patents, Biovail says